Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95(7):927–37.
Article
CAS
PubMed
Google Scholar
Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003;12(6):362–7.
Article
PubMed
Google Scholar
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995;270(5241):1491–4.
Article
CAS
PubMed
Google Scholar
Dihge L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L, et al. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat. 2008;109(2):255–62.
Article
CAS
PubMed
Google Scholar
Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst. 2006;98(10):671–80.
Article
CAS
PubMed
Google Scholar
Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB, et al. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res. 2009;15(6):2098–106.
Article
CAS
PubMed
Google Scholar
Su Q, Hu S, Gao H, Ma R, Yang Q, Pan Z, et al. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncology. 2008;75(3–4):159–68.
Article
CAS
PubMed
Google Scholar
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96(12):926–35.
Article
CAS
PubMed
Google Scholar
Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell. 2004;5(6):597–605.
Article
CAS
PubMed
Google Scholar
Miller WR, Hulme MJ, Bartlett JM, MacCallum J, Dixon JM. Changes in messenger RNA expression of protein kinase A regulatory subunit ialpha in breast cancer patients treated with tamoxifen. Clin Cancer Res. 1997;3(12 Pt 1):2399–404.
CAS
PubMed
Google Scholar
Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M, et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J. 2007;26(15):3534–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dudek P, Picard D. Genomics of signaling crosstalk of estrogen receptor alpha in breast cancer cells. PLoS ONE. 2008;3(3), e1859.
Article
PubMed
PubMed Central
Google Scholar
de Leeuw R, Flach K, Bentin Toaldo C, Alexi X, Canisius S, Neefjes J, et al. PKA phosphorylation redirects ERalpha to promoters of a unique gene set to induce tamoxifen resistance. Oncogene. 2013;32(30):3543–51.
Article
PubMed
Google Scholar
Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, et al. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol. 2009;217(3):372–9.
Article
CAS
PubMed
Google Scholar
Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van’t Veer LJ et al. PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat. 2011;125(1):1-12.
Bostner J, Skoog L, Fornander T, Nordenskjold B, Stal O. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res. 2010;16(5):1624–33.
Article
CAS
PubMed
Google Scholar
Rich TC, Fagan KA, Tse TE, Schaack J, Cooper DM, Karpen JW. A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell. Proc Natl Acad Sci U S A. 2001;98(23):13049–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 2002;295(5560):1711–5.
Article
CAS
PubMed
Google Scholar
Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res. 2004;95(1):67–75.
Article
CAS
PubMed
Google Scholar
Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science. 2002;298(5594):834–6.
Article
CAS
PubMed
Google Scholar
Rich TC, Tse TE, Rohan JG, Schaack J, Karpen JW. In vivo assessment of local phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP sensors. J Gen Physiol. 2001;118(1):63–78.
Article
CAS
PubMed
PubMed Central
Google Scholar
Carr DW, Stofko-Hahn RE, Fraser ID, Bishop SM, Acott TS, Brennan RG, et al. Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J Biol Chem. 1991;266(22):14188–92.
CAS
PubMed
Google Scholar
Newlon MG, Roy M, Morikis D, Carr DW, Westphal R, Scott JD, et al. A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes. EMBO J. 2001;20(7):1651–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Newlon MG, Roy M, Morikis D, Hausken ZE, Coghlan V, Scott JD, et al. The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat Struct Biol. 1999;6(3):222–7.
Article
CAS
PubMed
Google Scholar
Gold MG, Lygren B, Dokurno P, Hoshi N, McConnachie G, Tasken K, et al. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol Cell. 2006;24(3):383–95.
Article
CAS
PubMed
Google Scholar
Kinderman FS, Kim C, von Daake S, Ma Y, Pham BQ, Spraggon G, et al. A dynamic mechanism for AKAP binding to RII isoforms of cAMP-dependent protein kinase. Mol Cell. 2006;24(3):397–408.
Article
CAS
PubMed
PubMed Central
Google Scholar
Beene DL, Scott JD. A-kinase anchoring proteins take shape. Curr Opin Cell Biol. 2007;19(2):192–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hasegawa K, Ono T, Matsushita H, Shimono M, Noguchi Y, Mizutani Y, et al. A-kinase anchoring protein 3 messenger RNA expression in ovarian cancer and its implication on prognosis. Int J Cancer. 2004;108(1):86–90.
Article
CAS
PubMed
Google Scholar
Sharma S, Qian F, Keitz B, Driscoll D, Scanlan MJ, Skipper J, et al. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecol Oncol. 2005;99(1):183–8.
Article
CAS
PubMed
Google Scholar
Chiriva-Internati M, Ferrari R, Yu Y, Hamrick C, Gagliano N, Grizzi F, et al. AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol. 2008;140(4):465–8.
Article
CAS
PubMed
Google Scholar
Frank B, Wiestler M, Kropp S, Hemminki K, Spurdle AB, Sutter C, et al. Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst. 2008;100(6):437–42.
Article
CAS
PubMed
Google Scholar
Wirtenberger M, Schmutzhard J, Hemminki K, Meindl A, Sutter C, Schmutzler RK, et al. The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. Carcinogenesis. 2007;28(2):423–6.
Article
CAS
PubMed
Google Scholar
Hu JK, Wang L, Li Y, Yang K, Zhang P, Chen XZ, et al. The mRNA and protein expression of A-kinase anchor proteins 13 in human colorectal cancer. Clin Exp Med. 2010;10(1):41–9.
Article
CAS
PubMed
Google Scholar
Wirtenberger M, Tchatchou S, Hemminki K, Klaes R, Schmutzler RK, Bermejo JL, et al. Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer. Carcinogenesis. 2006;27(3):593–8.
Article
CAS
PubMed
Google Scholar
Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van’t Veer LJ, et al. PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat. 2011;125(1):1–12.
Article
CAS
PubMed
Google Scholar
Zwart W, Rondaij M, Jalink K, Sharp ZD, Mancini MA, Neefjes J, et al. Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1. Mol Endocrinol. 2009;23(9):1335–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. BMJ. 2002;325(7365):648–51.
Article
PubMed
Google Scholar
Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol. 2005;23(4):732–40.
Article
CAS
PubMed
Google Scholar
Zwart W, Griekspoor A, Rondaij M, Verwoerd D, Neefjes J, Michalides R. Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha. Mol Cancer Ther. 2007;6(5):1526–33.
Article
CAS
PubMed
Google Scholar
Förster T. Zwischenmolekulare energiewandering und fluoreszenz. Annalen Physik. 1948;6:55–75.
Article
Google Scholar
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–600.
Article
PubMed
Google Scholar
Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996;15(9):2174–83.
CAS
PubMed
PubMed Central
Google Scholar
Boylan M, van den Berg HW, Lynch M. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann Oncol. 1998;9(2):205–11.
Article
CAS
PubMed
Google Scholar
Huang SY, Tsai ML, Chen GY, Wu CJ, Chen SH. A systematic MS-based approach for identifying in vitro substrates of PKA and PKG in rat uteri. J Proteome Res. 2007;6(7):2674–84.
Article
CAS
PubMed
Google Scholar
Rubino D, Driggers P, Arbit D, Kemp L, Miller B, Coso O, et al. Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action. Oncogene. 1998;16(19):2513–26.
Article
CAS
PubMed
Google Scholar
Carnegie GK, Smith FD, McConnachie G, Langeberg LK, Scott JD. AKAP-Lbc nucleates a protein kinase D activation scaffold. Mol Cell. 2004;15(6):889–99.
Article
CAS
PubMed
Google Scholar
Jin J, Smith FD, Stark C, Wells CD, Fawcett JP, Kulkarni S, et al. Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol. 2004;14(16):1436–50.
Article
CAS
PubMed
Google Scholar
Diviani D, Abuin L, Cotecchia S, Pansier L. Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J. 2004;23(14):2811–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Miller WR. Regulatory subunits of PKA and breast cancer. Ann N Y Acad Sci. 2002;968:37–48.
Article
CAS
PubMed
Google Scholar
Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer. 2000;83(6):782–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer. 2003;88(9):1400–2.
Article
CAS
PubMed
PubMed Central
Google Scholar